Evidence map›Paper›PMID 38211588›Full record

ArticleMolecular cell2024

Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma.

Lianxin Hu, Yanfeng Zhang, Lei Guo, Hua Zhong, Ling Xie, Jin Zhou, Chengheng Liao, Hongwei Yao, Jun Fang, Hongyi Liu and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 2 countries.

Lianxin HuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Yanfeng ZhangQuantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lei GuoQuantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Hua ZhongDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Lyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ling XieDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA.
Jin ZhouDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Chengheng LiaoDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Hongwei YaoDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Jun FangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Hongyi LiuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cheng ZhangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Hui ZhangDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Xiaoqiang ZhuDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Maowu LuoDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Alex von KriegsheimCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Bufan LiDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Weibo LuoDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Xuewu ZhangDepartment of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Xian ChenDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA.
Joshua T MendellDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lin XuQuantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Payal KapurDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Albert S BaldwinLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
James BrugarolasSimmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Qing ZhangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: qing.zhang@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USUniversity of North Carolina at Chapel Hill · USEdinburgh Cancer Research · GBHoward Hughes Medical Institute · USSouthwestern Medical Center · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Payal Kapur, Payal Kapur · 2016 to 2026
$24.7M
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating CellsR35CA197684 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY · 2016 to 2022
$5.8M
Mechanisms of Metabolic Gene Mutations in CancerR01CA163834 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY · 2012 to 2023
$3.1M
Novel regulatory mechanisms and agonists of STINGR01CA273595 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Xiaochen Bai, CHUO CHEN · 2023 to 2026
$2.7M
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancerR01CA211732 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, QING · 2017 to 2021
$2.1M
Identification of DCLK2-TBK1 signaling axis as a potential therapeutic target in kidney cancerR01CA284591 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Qing Zhang · 2023 to 2026
$1.9M
Deciphering the non-canonical function of the histone methyltransferase G9a in the etiology of ADR21AG071229 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHEN, XIAN · 2021 to 2022
$428k
NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA163834NCI NIH HHS R01 CA211732NCI NIH HHS R01 CA273595NCI NIH HHS R01 CA284591NCI NIH HHS R35 CA197684NIA NIH HHS R21 AG071229
6 · The paper itself

Abstract

TANK-binding kinase 1 (TBK1) is a potential therapeutic target in multiple cancers, including clear cell renal cell carcinoma (ccRCC). However, targeting TBK1 in clinical practice is challenging. One approach to overcome this challenge would be to identify an upstream TBK1 regulator that could be targeted therapeutically in cancer specifically. In this study, we perform a kinome-wide small interfering RNA (siRNA) screen and identify doublecortin-like kinase 2 (DCLK2) as a TBK1 regulator in ccRCC. DCLK2 binds to and directly phosphorylates TBK1 on Ser172. Depletion of DCLK2 inhibits anchorage-independent colony growth and kidney tumorigenesis in orthotopic xenograft models. Conversely, overexpression of DCLK2

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCarcinogenesisCell Line, TumorCell ProliferationCell Transformation, NeoplasticDoublecortin-Like KinasesGene Expression Regulation, NeoplasticHumansProtein Serine-Threonine KinasesRNA, Small InterferingDCLK2 protein, humanDoublecortin-Like KinasesProtein Serine-Threonine KinasesRNA, Small InterferingTBK1 protein, humanccRCCDCLK2NMD pathwayoncogeneTBK1

Identifiers

PMID38211588
PMCPMC10922811
OpenAlexW4390694488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.